LTR Pharma advances SPONTAN program with ethics approval for Phase 2 clinical trial

LTR Pharma (ASX:LTP) has secured ethics approval for the next stage of clinical development of its fast-acting erectile dysfunction therapy, paving the way for recruitment to begin early next year and marking another step in the company’s expansion into global markets. …